NEW YORK (GenomeWeb News) – Ambry Genetics will use Agilent Technologies' SureSelect Target Enrichment System for the exome sequencing services it provides for its customers, the firms announced today.
"With Agilent’s SureSelect, Ambry Genetics is offering whole exome capture services for cancer markers, drug response, and Mendelian disease gene discovery," Ardy Arianpour, VP of business development for Ambry, said in a statement. "Ambry’s exome sequencing services deliver state of the art bioinformatics which include variant filtering, annotation, and interpretation of candidate mutations."
Financial and other terms of the alliance were not disclosed.
Agilent launched the SureSelect platform in 2009 and now includes a portfolio of 21 catalog and custom target enrichment products, the firms said.
A couple of months ago, Agilent announced that Expression Analysis was named a certified service provider for the SureSelect Target Enrichment System for next-generation sequencing. That followed BGI becoming a CSP for the platform earlier in the year.